This study is currently not recruiting participants.

A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent Clear Cell Carcinoma of the Ovary Fallopian Tube or Peritoneum

Investigating an investigational medication for recurrent ovarian and related cancers

Not Recruiting
18 years - 100 years
Female
Phase N/A
1 Location

Brief description of study.

This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse.

Detailed description of study

The purpose of this study is to evaluate the anti-tumor activity of cabozantinib (XL184) (cabozantinib-s-malate) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective tumor response (complete or partial).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Recurrent Clear Cell Carcinoma of the Ovary Fallopian Tube or Peritoneum
  • Age: 18 years - 100 years
  • Gender: Female

This study investigates an investigational medication for women with ovarian, fallopian tube, or primary peritoneal cavity cancer that has returned or is worsening. These types of cancer can be challenging to treat, especially when they come back after initial treatment. The purpose of this study is to see how well the investigational medication works in stopping the growth of these cancers.

Participants in this study will receive the investigational medication to assess its effects on their cancer. The study will measure how many patients live without their cancer getting worse for at least 6 months and how many show a reduction in tumor size, either completely or partially.

  • Who can participate: Women aged 18 and older with recurrent or persistent clear cell ovarian cancer may be eligible to participate.
  • Study details: Participants will receive cabozantinib-s-malate to evaluate its effectiveness. If a placebo is used, it will be an inactive substance that looks like the investigational medication. The study will monitor tumor response and progression-free survival.
Updated on 19 Feb 2024. Study ID: 1506000856 (NRG-GY001)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team